Doctor Responsible for Endometriosis Biomarker Discovery to Lead Seminar; Team to Exhibit & Answer Questions at Booth #325!

 EtegrityPlus_ASRMConference

BALTIMORE (October 16, 2015) – Innovative Reproductive Solutions, the leader in providing cutting-edge diagnostic tests for women’s reproductive health, will exhibit at the annual American Society of Reproductive Medicine Conference (http://www.asrmannualmeeting.org) October 17 – 21. Held at the Baltimore Convention Center, the ASRM Conference brings over 200 exhibitors from 23 countries to discuss the latest research on reproductive innovations and network with colleagues in the field.

“I have been fortunate enough to attend the ASRM Conference for the last 25 years,” says Ellen Berman, Vice President of Innovative Reproductive Solutions. “It is our biggest show of the year, and I am especially thrilled to show attendees the Etegrity Plus test. This is a great opportunity and platform to show this new technology, and we look forward to connecting with our existing and new customers.”

Etegrity Plus is the first test for endometriosis with high sensitivity and specificity, especially useful in women with unexplained IVF failure or infertility. Validation studies have found a high concordance between this test and the findings of endometriosis or hydrosalpinges (blocked tubes). Etegrity Plus combines the known biomarker Beta-3 integrin, with a newly discovered biomarker, BCL6.

Endometriosis, one of the top 3 causes of infertility and affecting approximately 176 million women worldwide, is a painful, chronic disease
that occurs when tissue similar to that which lines the uterus is found outside the uterus. The resulting inflammation can cause pain, infertility, scar tissue formation, adhesions, and more. More than 6 million people in the United States are affected by infertility; it is estimated 15-30% of women undergoing infertility evaluation have no cause identified. Evidence suggests up to 80% of women with unexplained infertility have implantation defects, much of which is caused by endometriosis.

The team behind Etegrity Plus (http://www.etegrityplus.com) will meet with media, as well as medical professionals, at Booth #325 in Swing Hall to answer questions and provide additional information about the groundbreaking test. The team will be sharing the booth with parent company Sepal Reproductive International.

In addition to the Etegrity Plus team exhibiting at ASRM, Dr Bruce Lessey, responsible for discovering the BCL6 gene repressive biomarker, will be speaking on three separate panels during the Conference. A recipient of the 2014 ASRM Star Award for dedicating hours of time and service to shape ASRM into the leading Society for reproductive medicine, Dr Lessey’s schedule is as follows:

Monday, October 19

Noon (12pm)

ORAL ABSTRACT SESSION O-16: Granulocyte-Macrophage Colony-Stimulating Factor is Cycle-Regulate in Human Endometrium & Dysregulated in Women with Endometriosis

Location: Baltimore Convention Center, Room 338

1:15pm – 2:15pm

INTERACTIVE SESSION: Endometriosis in the Infertile Patient

Location: Baltimore Convention Center, Room 310

Tuesday, October 20

11:15am

Abstract Moderator, ORAL ABSTRACT SESSION O-175: Exome Sequencing of Women with Surgically Confirmed Endometriosis Identifies New Candidate Genes

Location: Baltimore Convention Center, Rooms 327-329

To undergo the Etegrity Plus test, a physician will ask their patient to determine when she is ovulating, by using a commercially available ovulation detection test administered at home. The physician will then collect a sample of the uterine lining 7 to 11 days after the ovulation test is positive. The sample is then sent to Pathology Consultants, the only licensed lab for the Etegrity Plus test. Patients may also order the kit from Etegrity Plus, and take it to their physician to process.

Patients are encouraged to contact their doctor to request the Etegrity Plus test. Physicians interested in providing the Etegrity Plus test are invited to contact Ellen.etegrityplus@gmail.com.

For more information, visit www.etegrityplus.com.

 

About Innovative Reproductive Solutions / Etegrity Plus: 

Innovative Reproductive Solutions is a distinguished leader in the design, discovery, and marketing of innovative medical products, committed to bringing customers the latest advances in diagnostic testing devices to promote the health and wellbeing of women. Innovative Reproductive Solutions is a privately held, women-owned company based in Boston, Massachusetts. With over 20 years of experience in the women’s reproductive health industry, IRS continues to expand its product line and reinforce its commitment to becoming a leader in women’s healthcare by bringing the most advanced technologies and devices to the medical industry. Innovative Reproductive Solutions is the exclusive retailer of the E-tegrity test and the Etegrity Plus test. For more information, visit http://EtegrityPlus.com.

Etegrity Plus Social Media Links:
Facebook: https://www.facebook.com/EtegrityPlus
Twitter: https://twitter.com/EtegrityPlus

About the American Society of Reproductive Medicine:

ASRM is a multidisciplinary organization dedicated to the advancement of the science and practice of reproductive medicine. The Society accomplishes its mission through the pursuit of excellence in education and research and through advocacy on behalf of patients, physicians, and affiliated health care providers. The Society is committed to facilitating and sponsoring educational activities for the lay public and continuing medical education activities for professionals who are engaged in the practice of and research in reproductive medicine. In May 2014, the ASRM joined into official relations with the World Health Organization (WHO) as a Non-Governmental Organization (NGO). For more information, visit https://www.asrm.org and http://www.asrmannualmeeting.org.